Opens in a new tab or window Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors ... "We're not really sure about the right sequence. We don't ...

Oral cancer remains a serious global health issue, accounting for a significant portion of head and neck cancer cases ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by its partner Takeda (TSE:4502/NYSE:TAK). Takeda received a national ...

NECVAX-NEO1 is a personalized bacteria-based oral DNA therapeutic vaccine ... In the phase 1 study, 5 patients with melanoma, renal cell cancer, or head and neck cancer, who have been on CPI treatment ...

The initiative will include local biomarker testing. Vietnam’s Tam Anh General Hospital has been designated as the first ...

Repare Therapeutics (RPTX) reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of ...

Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...